Advertisement

Chemotherapy

Volume 7 Cancer Chemotherapy I

  • K. Hellmann
  • T. A. Connors

Table of contents

  1. Front Matter
    Pages i-xii
  2. Emil Frei III
    Pages 1-17
  3. Norbert Brock
    Pages 19-50
  4. Jennifer A. C. Sykes
    Pages 83-88
  5. Nicholas R. Bachur
    Pages 105-111
  6. Wolfgang Sadée
    Pages 113-117
  7. John M. Venditti, Mary K. Wolpert-DeFilippes
    Pages 129-147
  8. M.J. Cleare
    Pages 149-157
  9. Phillip S. Schein, Tom Anderson, Mary G. McMenamin, Joan Bull
    Pages 159-166
  10. K. Hellmann
    Pages 183-186
  11. G. E. Adams, J. Denekamp, J. E. Fowler
    Pages 187-206
  12. J. Rygard, Hanne S. Hansen
    Pages 207-210
  13. J. L. Foster, R. L. Willson
    Pages 215-222
  14. G. C. Easty, T. J. Powles, M. Dowsett, D. M. Easty, A. M. Neville
    Pages 239-241
  15. Allan J. Schutt, Charles G. Moertel
    Pages 249-254
  16. Michael D. Walker
    Pages 271-275
  17. John Garfield
    Pages 289-293
  18. L. J. Haňka, D. G. Martin, P. F. Wiley, G. L. Neil
    Pages 303-308
  19. Bridget T. Hill, L. A. Price, J. H. Goldie
    Pages 309-314
  20. Margaret Fox
    Pages 315-322
  21. J. Fuska, P. Vesely, L. Ivanickaja, A. Fuskova
    Pages 327-333
  22. B. J. Phillips, P. J. Cox
    Pages 335-340
  23. I.C.M. MacLennan on behalf of the British Medical Research Council’s Working Party on Leukaemia in Childhood
    Pages 355-358
  24. Jean Francois Bach
    Pages 359-360
  25. D. A. L. Davies
    Pages 361-361
  26. Back Matter
    Pages 363-364

About this book

Introduction

The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, expansion has been rapid, for example in cephalosporins, pen­ icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es­ pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is receiving increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu­ losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur­ rent progress in chemotherapy.

Keywords

cancer chemotherapy kinetics pharmacokinetics research resistance toxicity

Editors and affiliations

  • K. Hellmann
    • 1
  • T. A. Connors
    • 2
  1. 1.Westminster Hospital and Imperial Cancer Research FundUK
  2. 2.Chester Beatty Research InstituteUK

Bibliographic information

Industry Sectors
Pharma
Chemical Manufacturing
Biotechnology
Consumer Packaged Goods